Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Just weeks before its GammaDelta buyout, Takeda paid $100 million upfront for a license to Adaptimmune's SPEAR T-cell platform across five solid-tumor…
Takeda completed the exercise of its option to fully acquire GammaDelta Therapeutics, integrating two Vδ1 gamma-delta platforms into the company's expanding…
Takeda Pharmaceutical Company Limited Form 6-K furnished to the SEC on October 1, 2025, reporting the decision to discontinue cell therapy research and the…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Takeda exercised its 2017 option to acquire UK-based GammaDelta Therapeutics, gaining its allogeneic Vdelta1 gamma-delta T-cell platforms (blood- and tissue-derived) plus early-stage cell therapy programs for solid tumors. Financial terms were undisclosed (estimated ~$350M based on the prior option/payment structure). POST-CLOSE OUTCOME: on October 1, 2025 Takeda announced it would discontinue its cell therapy research as part of a strategic portfolio prioritization, recognizing an impairment loss of approximately JPY 58.0 billion primarily related to intangible assets associated with the gamma-delta T-cell therapy platform acquired in this deal. Takeda had no active cell therapy clinical trials at that point and said it would seek an external partner for the platform — effectively a write-down and wind-down of the acquired program roughly four years after the buyout.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / GammaDelta Therapeutics Limited (this deal) | 2021 | $350M | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2021 deals · Takeda Pharmaceutical Company Ltd. deals · Oncology deals